Collegium Pharmaceutical Stock Price, News & Analysis (NASDAQ:COLL)

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical Inc (NASDAQ:COLL) posted its quarterly earnings results on Wednesday, August, 7th. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. The specialty pharmaceutical company earned $75.04 million during the quarter, compared to analysts' expectations of $75.77 million. Collegium Pharmaceutical had a negative net margin of 7.45% and a negative return on equity of 26.10%. The business's quarterly revenue was up 2.7% on a year-over-year basis. During the same period last year, the company posted ($0.40) earnings per share. View Collegium Pharmaceutical's Earnings History.

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Collegium Pharmaceutical.

6 brokerages have issued 12-month price targets for Collegium Pharmaceutical's stock. Their forecasts range from $22.00 to $33.00. On average, they expect Collegium Pharmaceutical's share price to reach $26.20 in the next twelve months. This suggests a possible upside of 117.8% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.

Media coverage about COLL stock has been trending somewhat negative recently, InfoTrie reports. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Collegium Pharmaceutical earned a coverage optimism score of -1.2 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Collegium Pharmaceutical.

Collegium Pharmaceutical saw a decline in short interest in the month of September. As of September 15th, there was short interest totalling 2,810,000 shares, a decline of 7.0% from the August 15th total of 3,020,000 shares. Based on an average daily trading volume, of 275,600 shares, the short-interest ratio is currently 10.2 days. Approximately 10.1% of the shares of the stock are short sold. View Collegium Pharmaceutical's Current Options Chain.

Some companies that are related to Collegium Pharmaceutical include Uniqure (QURE), Pacira Biosciences (PCRX), Alder Biopharmaceuticals (ALDR), Insmed (INSM), Tricida (TCDA), Aimmune Therapeutics (AIMT), Nabriva Therapeutics (NBRV), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK), BELLUS Health (BLUSF) and Enanta Pharmaceuticals (ENTA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), Celgene (CELG), NVIDIA (NVDA), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Synergy Pharmaceuticals (SGYP), GW Pharmaceuticals PLC- (GWPH), Micron Technology (MU), Bausch Health Companies (BHC) and Advanced Micro Devices (AMD).

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of COLL stock can currently be purchased for approximately $12.03.

Collegium Pharmaceutical has a market capitalization of $402.66 million and generates $280.41 million in revenue each year. The specialty pharmaceutical company earns $-39,130,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.View Additional Information About Collegium Pharmaceutical.

The official website for Collegium Pharmaceutical is http://www.collegiumpharma.com/.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.